Fenwick Represents MRL Ventures in ATB Therapeutics’ €54 Million Series A Financing

Fenwick represented MRL Ventures, the therapeutics-focused corporate venture fund of Merck & Co., in ATB Therapeutics’ €54 million Series A financing. The round was co-led by EQT Life Sciences and MRL Ventures with participation from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and historical investors.

ATB Therapeutics, a biotechnology company dedicated to the discovery and development of novel antibody therapies, will use the funds to propel the clinical development of oncology as well as immunology therapeutics derived from ATB’s proprietary ATBioFarm platform. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partner Ian Goldstein and included associate Ethan MacKay.